KIT and gastrointestinal stromal tumor: Sunitinib and dovitinib inhibited viability of GIST cells dependent on the KIT exon 13 V654A secondary mutation, with IC50 values lower than 500 nM (IC50 45 nM and 250 nM, respectively).